Upcoming FDA Events for Belite Bio
Belite Bio (BLTE) has upcoming FDA regulatory milestones for Tinlarebant. The table below outlines estimated target dates and event types for these pending regulatory actions.
Belite Bio's Drug in the FDA Approval Process
This section highlights FDA-related milestones and regulatory updates for drugs developed by Belite Bio (BLTE).
Over the past two years, Belite Bio has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
Tinlarebant. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Tinlarebant FDA Regulatory Timeline and Events
Tinlarebant is a drug developed by Belite Bio for the following indication: In Stargardt Disease.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- Tinlarebant
- Announced Date:
- November 20, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced that the U.S. Food and Drug Administration (FDA) has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified during FDA’s ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027.
AI Summary
Belite Bio said the U.S. Food and Drug Administration (FDA) has extended its review of the company’s application for tinlarebant to treat Stargardt disease type 1 (STGD1) by three months. The new target date for the FDA’s decision is May 12, 2027. The agency needs more time to review information submitted in support of the application.
If the FDA finds no major deficiencies in its ongoing review, it plans to tell Belite Bio by April 12, 2027, about proposed product-labeling requests and any expected postmarketing requirements. These are requests for additional steps or studies after a drug is approved, if needed. Tinlarebant is an oral drug designed to reduce the buildup of harmful substances in the eye that are linked to retinal disease. The company said it remains committed to working with the FDA and believes the clinical evidence supports the treatment’s potential for people with STGD1. The extended review timeline does not mean the FDA has approved the drug; the agency’s decision is still pending.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- October 14, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced Marketing Authorization Application (MAA) submissions to the regulatory authorities in Singapore, the United Kingdom, and Switzerland for tinlarebant in the treatment of Stargardt disease type 1 (STGD1).
AI Summary
Belite Bio has submitted marketing authorization applications for tinlarebant to regulators in Singapore, the United Kingdom, and Switzerland. The applications were filed through the Access Consortium, a partnership that allows the three countries’ health authorities to review the treatment in parallel and support coordinated, timely assessments.
Tinlarebant is an investigational, once-daily oral medicine for Stargardt disease type 1 (STGD1), a rare inherited condition caused by ABCA4 gene mutations. The disease leads to progressive, irreversible vision loss, and there are currently no approved treatments in the three countries. If authorized, tinlarebant could become the first approved treatment for STGD1 in Singapore, the UK, and Switzerland.
Belite Bio says study data showed tinlarebant slowed the growth of retinal lesions compared with placebo. The company described the submissions as an important step toward making the medicine available to patients worldwide. The applications are now subject to review by the respective regulatory authorities; approval and availability are not guaranteed.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- September 28, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced that its data will be presented at the Euretina Innovation Spotlight (EIS) being held on September 30, 2026, and Euretina being held on October 1-4, 2026, in Vienna, Austria.
AI Summary
Belite Bio, Inc. announced that it will present data at two retinal research meetings in Vienna, Austria. The Euretina Innovation Spotlight takes place September 30, 2026, followed by the Euretina meeting from October 1–4.
At the Innovation Spotlight, Belite Bio Chief Medical Officer Hendrik Scholl will give a company overview during a session on inherited and rare retinal diseases. His presentation is scheduled for September 30 from 2:28 to 3:06 p.m. CEST at the Vienna Congress & Convention Center.
On October 4, Michel Michaelides of Moorfields Eye Hospital and UCL Institute of Ophthalmology will present topline results from the Phase 3 DRAGON study of tinlarebant in adolescents with Stargardt disease. Tinlarebant is an oral treatment designed to reduce harmful vitamin A-related substances in the retina. Stargardt disease is an inherited condition that causes progressive loss of central vision, and there are currently no approved treatments.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- September 8, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour, and Welfare (MHLW) in Japan for tinlarebant in Stargardt disease type 1 (STGD1).
AI Summary
Belite Bio, Inc. has submitted an application to Japan’s Ministry of Health, Labour, and Welfare for tinlarebant, an investigational once-daily oral treatment for Stargardt disease type 1 (STGD1). This rare inherited eye disease is linked to ABCA4 gene mutations and causes progressive, irreversible vision loss. An estimated 9,500 people in Japan have STGD1, and no treatment is currently approved there.
Tinlarebant has Japan’s SAKIGAKE designation, which supports faster review of promising medicines for serious diseases. If approved, it could become Japan’s first approved treatment for STGD1 and the first ophthalmology medicine approved through the SAKIGAKE program. Belite says study results showed the drug slowed the growth of retinal lesions compared with placebo. The company says it will work with regulators and prepare for potential delivery to patients. The application is now under review, and approval is not guaranteed.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- August 11, 2026
- Target Action Date:
- February 12, 2027
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced that The FDA has set a Prescription Drug User Fee Act (PDUFA) date of February 12, 2027.
AI Summary
Belite Bio announced that the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant and granted it Priority Review for Stargardt Disease Type 1 (STGD1). The FDA’s target decision date is February 12, 2027.
The application is supported by results from the Phase 3 DRAGON trial. Tinlarebant reduced the growth rate of atrophic retinal lesions by 35.7% compared with placebo, a result the company described as statistically significant and clinically meaningful. The drug was generally well tolerated in clinical trials, with side effects consistent with how it works.
STGD1 is a rare inherited eye disease that causes progressive, irreversible vision loss and affects an estimated 53,000 people in the United States. There is currently no approved treatment. If the FDA approves tinlarebant, it would be the first approved treatment for the disease. The once-daily oral drug is designed to reduce harmful substances that build up in the retina.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- August 11, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt Disease Type 1 (STGD1).
AI Summary
Belite Bio announced that the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant and granted it Priority Review for Stargardt Disease Type 1 (STGD1). The FDA’s target decision date is February 12, 2027.
The application is supported by results from the Phase 3 DRAGON trial. Tinlarebant reduced the growth rate of atrophic retinal lesions by 35.7% compared with placebo, a result the company described as statistically significant and clinically meaningful. The drug was generally well tolerated in clinical trials, with side effects consistent with how it works.
STGD1 is a rare inherited eye disease that causes progressive, irreversible vision loss and affects an estimated 53,000 people in the United States. There is currently no approved treatment. If the FDA approves tinlarebant, it would be the first approved treatment for the disease. The once-daily oral drug is designed to reduce harmful substances that build up in the retina.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- July 20, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced additional, positive secondary endpoint data from its Phase 3 DRAGON trial of tinlarebant in Stargardt disease type 1 (STGD1).
AI Summary
Belite Bio, Inc. reported more encouraging results from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1 (STGD1), a rare inherited eye disease that can lead to vision loss. The company said additional secondary endpoint data were positive, adding to earlier findings from the study. These results support the potential of tinlarebant as a treatment option for people living with STGD1, a condition with limited approved therapies.
The updated trial data are important because secondary endpoints can show how a treatment affects other measures of disease beyond the main study goal. Belite Bio said the findings strengthen the overall picture of benefit seen in the DRAGON trial. The company may use these results to support future development and possible regulatory discussions for tinlarebant.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- May 15, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc. announced that the Company will give an oral presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026) being held from May 21-23, 2026, in Nanjing, China.
AI Summary
Belite Bio, Inc. said it will give an oral presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026), taking place May 21-23, 2026, in Nanjing, China. The presentation will highlight previously reported positive topline results from the Phase 3 DRAGON trial, which studied tinlarebant as a treatment for Stargardt disease type 1 (STGD1).
In the trial, tinlarebant showed a 35.7% reduction in the growth rate of atrophic retinal lesions compared with placebo. The company also said the drug was generally well tolerated, with side effects that matched what is expected from its mechanism of action. These results support Belite Bio’s ongoing work on tinlarebant as a possible treatment for this rare eye disease.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- April 27, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced that the Company will give an oral presentation at the Retinal Therapeutics Innovation Summit being held on May 1, 2026, in Denver, Colorado.
AI Summary
Belite Bio, Inc. announced it will give an oral presentation at the Retinal Therapeutics Innovation Summit on May 1, 2026, in Denver, Colorado.
The presentation will cover the previously disclosed positive topline results from the Phase 3 DRAGON trial of tinlarebant for treating Stargardt disease type 1 (STGD1). In the study, tinlarebant produced a clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions versus placebo and showed a strong safety profile. A reduction of this size could help slow vision loss for people with STGD1.
Company executives and study investigators will present detailed data, explain the clinical meaning of the results, and discuss implications for patients and ongoing clinical development. The session gives clinicians, researchers, and investors a chance to learn more about tinlarebant’s effects and safety.
The presentation will be followed by a brief question-and-answer session. For media and investor inquiries: Jennifer Wu [email protected] and Julie Fallon [email protected].
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- January 27, 2026
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc nnounced the completion of enrollment of 60 subjects, including 15 Japanese subjects, in the Phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt disease type 1 (STGD1).
AI Summary
Belite Bio announced completion of enrollment of 60 adolescent subjects, including 15 Japanese participants, in the Phase 2/3 DRAGON II clinical trial of tinlarebant for Stargardt disease type 1 (STGD1). DRAGON II is a global, 24‑month, randomized, double‑masked, placebo‑controlled study that enrolled 12–20‑year‑old patients across Japan, the United States, and the United Kingdom. Participants were randomized 1:1 to receive tinlarebant or placebo, meeting the study’s targeted sample size.
The company thanked investigators, the adolescent participants, and their families for supporting the trial. Belite’s leadership noted that completing enrollment advances their clinical development program and that the study was implemented to align with requirements of the Japanese Pharmaceuticals and Medical Devices Agency, supporting potential regulatory paths in Japan while gathering data for adolescents globally.
Tinlarebant is an oral therapy designed to lower retinol transport to the eye and reduce formation of toxic bisretinoids. DRAGON II will evaluate its efficacy, safety, and tolerability in adolescent STGD1 patients.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- December 1, 2025
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced topline results from the global Phase 3 "DRAGON" trial of Tinlarebant, marking the first successful pivotal trial in patients with Stargardt disease type 1 (STGD1).
AI Summary
Belite Bio reported topline results from the global Phase 3 DRAGON trial showing Tinlarebant is the first therapeutic to demonstrate clinical efficacy in Stargardt disease type 1 (STGD1). In 104 adolescent patients (age 12–20) treated over 24 months, Tinlarebant reduced the growth rate of retinal atrophic lesions (measured as definitely decreased autofluorescence, DDAF, by fundus autofluorescence imaging) by about 36% versus placebo. The primary analysis reached statistical significance (p = 0.0033), and a post-hoc longitudinal analysis showed an even stronger signal (p < 0.0001).
Tinlarebant was generally well tolerated, with four treatment-related discontinuations and mostly mild ocular effects such as xanthopsia and delayed dark adaptation; visual acuity changed little over 24 months, consistent with disease course. Belite plans to pursue regulatory filing and will share more data at upcoming medical meetings.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- October 15, 2025
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc. announced that the Center for Drug Evaluation of China's National Medical Products Administration ("NMPA") has agreed to accept the New Drug Application (NDA) with priority review for Tinlarebant for the treatment of Stargardt disease based on the interim analysis results from the Phase 3 DRAGON trial.
AI Summary
Belite Bio, Inc. announced on October 15, 2025, that China’s National Medical Products Administration (NMPA) has agreed to accept its New Drug Application (NDA) for priority review of Tinlarebant to treat Stargardt disease. This decision is based on interim analysis results from the Phase 3 DRAGON trial.
The interim analysis demonstrated statistical significance in the trial’s primary endpoint, measuring the growth rate of atrophic eye lesions. The randomized, double-masked, placebo-controlled study enrolled 104 adolescent subjects across 11 jurisdictions with a 2:1 Tinlarebant-to-placebo ratio. Final topline data are expected in the fourth quarter of 2025 to support the full NDA submission.
Tinlarebant is an oral therapy that lowers retinol binding protein 4 to reduce vitamin A–based toxins in the eye. Priority review by the NMPA is a major milestone for Belite Bio and the Stargardt community, which has no approved treatments. If approved, Tinlarebant could become the first therapy for this degenerative eye disease.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- September 12, 2025
- Indication:
- In Stargardt Disease
Announcement
Belite Bio Inc announced the completion of the last subject visit in the Phase 3 DRAGON clinical trial evaluating Tinlarebant for the treatment of Stargardt disease type 1 (STGD1).
AI Summary
Belite Bio Inc announced the final subject visit was completed in its pivotal Phase 3 DRAGON trial of Tinlarebant for treating Stargardt disease type 1 (STGD1). Dr. Tom Lin, Chairman and CEO, said this milestone brings the company closer to offering the first approved therapy for this inherited macular degeneration and thanked patients, families, investigators, and study teams worldwide.
The DRAGON trial enrolled 104 adolescent subjects across 11 countries, including the U.S., U.K., Germany, France, Belgium, Switzerland, the Netherlands, China, Hong Kong, Taiwan, and Australia, with a 2:1 randomization of Tinlarebant versus placebo. Ninety-four subjects completed the study, with the last visit on September 11, 2025. The primary endpoint is the growth rate of atrophic lesions, and safety and tolerability of Tinlarebant will also be evaluated.
Belite Bio expects to report topline results from the DRAGON trial in the fourth quarter of 2025 and plans to file New Drug Applications in the first half of 2026.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- July 2, 2025
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phase 3 pivotal trial evaluating the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with geographic atrophy (GA) in dry age-related macular degeneration (AMD).
AI Summary
Belite Bio, Inc. announced that enrollment is now complete for its PHOENIX trial, a global, 24-month Phase 3 study. The trial will examine the safety and tolerability of Tinlarebant, an investigational oral treatment, and its ability to slow the growth of atrophic lesions in patients with geographic atrophy (GA) due to dry age-related macular degeneration (AMD).
This pivotal study enrolled 500 subjects from the United States, United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia. The completion of enrollment marks a key milestone in the development of Tinlarebant, which could offer hope for patients suffering from this serious, progressive eye condition that currently has no approved oral treatment. Researchers look forward to sharing the trial’s interim results and further insights into how Tinlarebant may help slow the progression of GA.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- May 21, 2025
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease (STGD1) based on the previously reported interim data from the ongoing Phase 3 DRAGON trial.
AI Summary
Belite Bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tinlarebant to treat Stargardt disease (STGD1). This designation was given based on promising interim results from the ongoing Phase 3 DRAGON trial. The trial’s results show that Tinlarebant has a strong safety profile and may help stabilize visual acuity in most adolescent patients with the condition. The drug’s potential to slow or improve the disease process marks a major milestone for patients who currently have no approved treatment options for STGD1.
The Breakthrough Therapy Designation supports an accelerated development and review process. With the DRAGON trial expected to complete by the fourth quarter of 2025, Belite Bio continues to work hard to bring a new, effective therapy to those affected by this serious, progressive eye disease.
Read Announcement- Drug:
- Tinlarebant
- Announced Date:
- February 27, 2025
- Indication:
- In Stargardt Disease
Announcement
Belite Bio, Inc announced that following a pre-specified Interim Analysis of the pivotal global Phase 3 "DRAGON" trial data of Tinlarebant in adolescent Stargardt disease patients, the Data Safety Monitoring Board (DSMB) has recommended the trial proceed without any modifications.
AI Summary
Belite Bio, Inc. announced an important milestone in its Phase 3 DRAGON trial for Tinlarebant in adolescent Stargardt disease patients. After a pre-specified interim analysis, the independent Data Safety Monitoring Board (DSMB) recommended that the trial proceed without any modifications. This means the current study design and sample size of 104 subjects will remain unchanged, as the data did not suggest a need for an increase.
The analysis was conducted after one year of assessments, showing that Tinlarebant is well-tolerated and that the visual acuity in most patients remained stable. The DSMB also advised that the current data be submitted for further regulatory review. The trial is on track to be completed by the fourth quarter of 2025, including a brief follow-up period after the final assessments.
Read Announcement
Belite Bio FDA Events - Frequently Asked Questions
As of now, Belite Bio (BLTE) has not received any FDA approvals for its therapy in the last two years.
In the past two years, Belite Bio (BLTE) has reported FDA regulatory activity for Tinlarebant.
The most recent FDA-related event for Belite Bio occurred on November 20, 2026, involving Tinlarebant. The update was categorized as "PDUFA Date," with the company reporting: "Belite Bio, Inc announced that the U.S. Food and Drug Administration (FDA) has informed the Company that (i) it has extended the review period for the New Drug Application (NDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1) by three months, with the extended Prescription Drug User Fee Act (PDUFA) action date being May 12, 2027, and (ii) if no major deficiencies are identified during FDA’s ongoing review, the FDA plans to communicate proposed labeling requests and any anticipated postmarketing requirement requests, if necessary, with the Company by April 12, 2027."
Currently, Belite Bio has one therapy (Tinlarebant) targeting the following condition: In Stargardt Disease.
More FDA Event Resources from MarketBeat
Companies With Recent FDA Events
FDA Event Stage Terminology & Abbreviation Guide
- NDA: New Drug Application
- ANDA: Abbreviated New Drug Application
- sNDA: Supplemental New Drug Application
- BLA: Biologics License Application
- sBLA: Supplemental Biologics License Application
- FDA Approved: Approved by the FDA
- EMA: European Medicines Agency
- CE Mark: European Union Certification
- NMPA: China National Medical Products Administration
- MHLW: Japanese Ministry of Health
- FDA Meeting: Consultation with FDA
- Pre-IND: Pre-Investigational New Drug Meeting
- Breakthrough Therapy: Special FDA designation for promising therapies
- Fast Track: Accelerated FDA approval pathway
- Orphan Drug: Designation for rare disease treatments
- RPD: Rare Pediatric Disease Designation
- RMAT: Regenerative Medicine Advanced Therapy
- DSMB Review: Data Safety Monitoring Board Review
- IDMC Review: Independent Data Monitoring Committee
- MAA: MHRA Marketing Authorization Application
- RTF: Refusal to File (Rejected Application)
- 510(k): FDA Clearance for Medical Devices
- Rolling Submission: Staggered regulatory review process
FDA progress for NASDAQ:BLTE last updated on 11/20/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data.